🟢 Biomea Fusion is trading 10.38% up today after completing COVALENT-211 enrollment

Biomea Fusion is trading 10.38% up at $1.75 after investors continued responding to the August 24 completion of enrollment in the COVALENT-211 Phase II icovamenib trial.

• The study enrolled 64 participants across 18 sites; primary endpoint data are expected in the first quarter of 2027.
• Shares gained 16.06% on August 24, while XBI rose 2.06% amid a broadly positive market session.
• Consecutive sharp gains suggest elevated activity; volume was unavailable, and enrollment remained the clearer catalyst.